Dr. O'Reilly Discusses Advancements in Early-Stage Pancreatic Cancer

Eileen O'Reilly, MD
Published: Friday, Dec 15, 2017



Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early-stage pancreatic cancer.

The major change for patients with early-stage pancreatic cancer is the combination of cytotoxic chemotherapy in the adjuvant setting. Data from ESPAC-4 study demonstrated that the addition of capecitabine to gemcitabine had an improvement in overall survival with low toxicity.
 
SELECTED
LANGUAGE


Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early-stage pancreatic cancer.

The major change for patients with early-stage pancreatic cancer is the combination of cytotoxic chemotherapy in the adjuvant setting. Data from ESPAC-4 study demonstrated that the addition of capecitabine to gemcitabine had an improvement in overall survival with low toxicity.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x